{"product_id":"semaglutide-consent-form-template-93233","title":"Semaglutide Consent Form Template – GLP-1 Weight Loss Injection, Patient Informed Consent \u0026 Medical Spa Form | PDF and Word","description":"\u003cp\u003eDocument informed patient consent for Semaglutide treatment with this professional Semaglutide Consent Form Template.\u003cbr\u003e\nDesigned for healthcare practices offering medically supervised GLP-1 treatment, this customizable form provides a structured way to document the purpose of treatment, treatment plan, potential benefits, side effects, serious risks, contraindications, alternatives, pregnancy considerations, voluntary participation, and patient authorization.\u003c\/p\u003e\n\u003cp\u003eThe form identifies Semaglutide as a GLP-1 receptor agonist and addresses its use for weight management and\/or management of type 2 diabetes.\u003c\/p\u003e\n\u003cp\u003eWHAT’S INCLUDED\u003cbr\u003e\nThis Semaglutide Consent Form includes:\u003cbr\u003e\n• Patient Name\u003cbr\u003e\n• Date of Birth\u003cbr\u003e\n• Date of Consent\u003cbr\u003e\n• Semaglutide Treatment Explanation\u003cbr\u003e\n• Purpose of Treatment\u003cbr\u003e\n• Treatment Plan\u003cbr\u003e\n• Potential Benefits\u003cbr\u003e\n• Common Side Effects\u003cbr\u003e\n• Serious Risk Disclosure\u003cbr\u003e\n• Contraindication \/ Medical History Section\u003cbr\u003e\n• Treatment Alternatives\u003cbr\u003e\n• Pregnancy \u0026amp; Breastfeeding Statement\u003cbr\u003e\n• Voluntary Participation\u003cbr\u003e\n• Patient Questions \u0026amp; Understanding\u003cbr\u003e\n• Consent \u0026amp; Authorization\u003cbr\u003e\n• Patient Signature \u0026amp; Date\u003cbr\u003e\n• Provider Name\u003cbr\u003e\n• Provider Signature \u0026amp; Date\u003c\/p\u003e\n\u003cp\u003eSEMAGLUTIDE TREATMENT EXPLANATION\u003cbr\u003e\nProvide patients with a straightforward introduction to the proposed treatment.\u003cbr\u003e\nThe template explains that Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and identifies treatment purposes including:\u003c\/p\u003e\n\u003cp\u003e✓ Chronic Weight Management\u003cbr\u003e\n✓ Appetite Regulation\u003cbr\u003e\n✓ Blood Sugar Control in Type 2 Diabetes\u003c\/p\u003e\n\u003cp\u003eTREATMENT PLAN\u003cbr\u003e\nThe form documents a treatment plan involving once-weekly subcutaneous administration, beginning at a lower dose and increasing as tolerated based on the provider's discretion.\u003cbr\u003e\nBecause dosing and treatment plans are patient-specific, this section should be reviewed and customized by the prescribing healthcare professional.\u003c\/p\u003e\n\u003cp\u003ePOTENTIAL BENEFITS\u003cbr\u003e\nHelp patients understand the potential goals of treatment.\u003cbr\u003e\nThe template identifies potential benefits including:\u003c\/p\u003e\n\u003cp\u003e• Weight Loss \u0026amp; Improved Metabolic Health\u003cbr\u003e\n• Improved Blood Sugar Control\u003cbr\u003e\n• Decreased Appetite\u003cbr\u003e\n• Reduced Food Cravings\u003c\/p\u003e\n\u003cp\u003eCOMMON SIDE EFFECT DISCLOSURE\u003cbr\u003e\nThe consent form includes a section informing patients that potential side effects may include:\u003cbr\u003e\n• Nausea\u003cbr\u003e\n• Vomiting\u003cbr\u003e\n• Diarrhea\u003cbr\u003e\n• Constipation\u003cbr\u003e\n• Abdominal Pain\u003cbr\u003e\n• Headache\u003cbr\u003e\n• Fatigue\u003c\/p\u003e\n\u003cp\u003eSERIOUS RISK DISCLOSURE\u003cbr\u003e\nThe template also contains a dedicated section identifying potentially serious risks, including:\u003cbr\u003e\n• Pancreatitis\u003cbr\u003e\n• Gallbladder Disease\u003cbr\u003e\n• Kidney Dysfunction\u003cbr\u003e\n• Medullary Thyroid Carcinoma\u003cbr\u003e\n• Allergic Reaction\u003cbr\u003e\n• Low Blood Sugar, particularly when combined with other glucose-lowering agents\u003c\/p\u003e\n\u003cp\u003eCONTRAINDICATION \/ MEDICAL HISTORY SECTION\u003cbr\u003e\nPrompt patients to disclose important medical history before treatment.\u003cbr\u003e\nThe form asks patients to inform their provider about:\u003c\/p\u003e\n\u003cp\u003e✓ Personal or Family History of Medullary Thyroid Carcinoma\u003cbr\u003e\n✓ Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)\u003cbr\u003e\n✓ History of Pancreatitis\u003cbr\u003e\n✓ Kidney Disease\u003cbr\u003e\n✓ Gallbladder Disease\u003c\/p\u003e\n\u003cp\u003eALTERNATIVES TO TREATMENT\u003cbr\u003e\nSupport the informed-consent process by documenting alternatives.\u003cbr\u003e\nThe template identifies alternatives including diet and exercise, other medications, or choosing not to receive treatment.\u003c\/p\u003e\n\u003cp\u003ePREGNANCY \u0026amp; BREASTFEEDING SECTION\u003cbr\u003e\nThe form contains a dedicated pregnancy and breastfeeding statement in which the patient certifies that they are not currently pregnant or breastfeeding and addresses contraception during treatment when applicable.\u003cbr\u003e\nThis section should be reviewed by the prescribing provider and customized to reflect current prescribing information and the practice's clinical protocols.\u003c\/p\u003e\n\u003cp\u003eVOLUNTARY PARTICIPATION\u003cbr\u003e\nThe template states that treatment is elective rather than an emergency procedure and that the patient may discontinue treatment.\u003cbr\u003e\nPATIENT QUESTIONS \u0026amp; UNDERSTANDING\u003cbr\u003e\nDocument that the patient had an opportunity to ask questions before consenting.\u003cbr\u003e\nThe form includes an acknowledgment that the patient's questions have been answered and that the patient understands the discussed risks, benefits, and alternatives.\u003c\/p\u003e\n\u003cp\u003eCONSENT \u0026amp; AUTHORIZATION\u003cbr\u003e\nComplete the informed-consent process with dedicated authorization and signature fields for:\u003cbr\u003e\n• Patient Signature\u003cbr\u003e\n• Patient Signature Date\u003cbr\u003e\n• Provider Name\u003cbr\u003e\n• Provider Signature\u003cbr\u003e\n• Provider Signature Date\u003c\/p\u003e\n\u003cp\u003eThe authorization confirms that the patient has read and understood the consent form and authorizes administration as prescribed by the provider.\u003c\/p\u003e\n\u003cp\u003ePERFECT FOR\u003cbr\u003e\n• Medical Weight Loss Clinics\u003cbr\u003e\n• GLP-1 Weight Management Programs\u003cbr\u003e\n• Med Spas\u003cbr\u003e\n• Medical Spas\u003cbr\u003e\n• Wellness Clinics\u003cbr\u003e\n• Physician Practices\u003cbr\u003e\n• Nurse Practitioner Practices\u003cbr\u003e\n• Telehealth Practices\u003cbr\u003e\n• Weight Management Centers\u003cbr\u003e\n• Healthcare Providers\u003cbr\u003e\n• Patient Intake \u0026amp; Onboarding\u003cbr\u003e\n• Semaglutide Treatment Programs\u003cbr\u003e\nCUSTOMIZABLE FOR YOUR PRACTICE\u003cbr\u003e\nPersonalize this template with your:\u003cbr\u003e\n• Practice Name\u003cbr\u003e\n• Patient Information\u003cbr\u003e\n• Provider Information\u003cbr\u003e\n• Treatment Protocols\u003cbr\u003e\n• Patient Education Information\u003cbr\u003e\n• Medical Disclosures\u003cbr\u003e\n• Practice-Specific Consent Language\u003cbr\u003e\n• Additional Patient Acknowledgments\u003c\/p\u003e\n\u003cp\u003eDIGITAL DOWNLOAD\u003cbr\u003e\nThis is a digital product. No physical item will be shipped.\u003cbr\u003e\nYour purchase includes a customizable 3-page Semaglutide Consent Form in PDF and Word formats.\u003c\/p\u003e\n\u003cp\u003eDownload the files and have an appropriately licensed healthcare professional review and customize the form for your practice, treatment protocols, patient population, and applicable state requirements before use.\u003c\/p\u003e\n\u003cp\u003eIMPORTANT MEDICAL \u0026amp; LEGAL DISCLAIMER\u003cbr\u003e\nThis template is provided for general informational, administrative, and document-preparation purposes only. It does not constitute medical, legal, prescribing, pharmacy, nursing, telehealth, FDA, or regulatory advice.\u003cbr\u003e\nUse of this template alone does not establish informed consent or guarantee compliance with applicable medical or legal requirements. Semaglutide prescribing, dispensing, administration, patient screening, informed consent, and monitoring must be performed in accordance with current prescribing information, applicable professional scope-of-practice requirements, and federal and state law.\u003c\/p\u003e\n\u003cp\u003eThe template's medical statements—including its treatment plan, benefits, risks, contraindication section, and pregnancy\/breastfeeding language—should be independently reviewed and updated by an appropriately qualified healthcare professional before use.\u003c\/p\u003e\n\u003cp\u003eThis template should not be used to determine whether a particular patient is medically eligible for Semaglutide and is not a substitute for an individualized medical evaluation or provider-patient discussion.\u003c\/p\u003e\n\u003cp\u003eDue to the nature of digital products, all sales are final.\u003c\/p\u003e","brand":"DocuBridge","offers":[{"title":"Default Title","offer_id":47147261493350,"sku":null,"price":5.99,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0736\/2586\/2246\/files\/il_fullxfull.8480587002_cww6.jpg?v=1788968620","url":"https:\/\/docubridgeadmin.com\/products\/semaglutide-consent-form-template-93233","provider":"DocuBridge","version":"1.0","type":"link"}